References

  1. Lynparza 100mg and 150mg film-coated tablets Summary of Product Characteristics, May 2018. Available at: https://www.medicines.org.uk/emc/product/9204/smpc. Last accessed February 2019.
  2. Lynparza 50mg hard capsules Summary of Product Characteristics, July 2018. Available at: https://www.medicines.org.uk/emc/product/6821/smpc. Last accessed February 2019.
  3. Ledermann, J. et al. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
  4. Pujade-Lauraine, E. et al. SOLO2/ENGOT-Ov21: A phase 3, randomised, double-blind, placebo-controlled trial of olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Lancet Oncol. 17, 30469–2 (2017).
  5. Gourley, C. et al. Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol 35 (poster related to suppl; abstr 5533) (2017).
  6. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014).
  7. Ledermann, J. A. et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 17, 1579–1589 (2016).
  8. Friedlander M, et al. 2018. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 119: 1075–1085 (supplementary appendix)
  9. Friedlander M, et al. 2018. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 119: 1075–1085
  10. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy | Guidance and guidelines | NICE. Available at: https://www.nice.org.uk/guidance/ta381/chapter/1-Recommendations. Last accessed February 2019.
  11. Scottish Medicines Consortium. Re-submission - olaparib, 50mg, hard capsules (Lynparza). SMC No. (1047/15). Available at: https://www.scottishmedicines.org.uk/media/2068/olaparib_lynparza_resub_final_oct_2016_revised_201016_for_website.pdf. Last accessed February 2019.
  12. Weil, M. K. & Chen, A. PARP Inhibitor Treatment in Ovarian and Breast Cancer. Curr. Probl. Cancer 35, 7–50 (2011).
  13. Aly, A. & Ganesan, S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J. Mol. Cell Biol. 3, 66–74 (2011).

GB-15722
Date of preparation: February 2019